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Background: Type 2 diabetes mellitus (T2DM) is a major cardiovascular disease (CVD) risk factor. Identification of
genetic risk factors for CVD is important to understand disease risk. Two recent genome-wide association study
(GWAS) meta-analyses in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium
detected CVD-associated loci.
Methods: Variants identified in CHARGE were tested for association with CVD phenotypes, including vascular
calcification, and conventional CVD risk factors, in the Diabetes Heart Study (DHS) (n = 1208; >80% T2DM affected).
This included 36 genotyped or imputed single nucleotide polymorphisms (SNPs) from DHS GWAS data. 28 coding
SNPs from 14 top CHARGE genes were also identified from exome sequencing resources and genotyped, along
with 209 coding variants from the Illumina HumanExome BeadChip genotype data in the DHS were also tested.
Genetic risk scores (GRS) were calculated to evaluate the association of combinations of variants with CVD measures.
Results: After correction for multiple comparisons, none of the CHARGE SNPs were associated with vascular
calcification (p < 0.0014). Multiple SNPs showed nominal significance with calcification, including rs599839 (PSRC1,
p = 0.008), rs646776 (CELSR2, p = 0.01), and rs17398575 (PIK3CG, p = 0.009). Additional COL4A2 and CXCL12 SNPs were
nominally associated with all-cause or CVD-cause mortality. Three SNPs were significantly or nominally associated with
serum lipids: rs3135506 (Ser19Trp, APOA5) with triglycerides (TG) (p = 5×10−5), LDL (p = 0.00070), and nominally with
high density lipoprotein (HDL) (p = 0.0054); rs651821 (5′UTR, APOA5) with increased TGs (p = 0.0008); rs13832449 (splice
donor, APOC3) associated with decreased TGs (p = 0.0015). Rs45456595 (CDKN2A, Gly63Arg), rs5128 (APOC3, 3′UTR), and
rs72650673 (SH2B3, Glu400Lys) were nominally associated with history of CVD, subclinical CVD, or CVD risk factors
(p < 0.010). From the exome chip, rs3750103 (CHN2, His204Arg/His68Arg) with carotid intima-medial thickness (IMT)
(p = 3.9×10−5), and rs61937878 (HAL, Val549Met) with infra-renal abdominal aorta CP (AACP) (p = 7.1×10−5). The
unweighted GRS containing coronary artery calcified plaque (CAC) SNPs was nominally associated with history of prior
CVD (p = 0.033; OR = 1.09). The weighted GRS containing SNPs was associated with CAC and myocardial infarction (MI)
was associated with history of MI (p = 0.026; OR = 1.15).
Conclusions: Genetic risk factors for subclinical CVD in the general population (CHARGE) were modestly associated
with T2DM-related risk factors and CVD outcomes in the DHS.
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Type 2 diabetes mellitus (T2DM) is a major public
health concern throughout the world. T2DM risk factors
include gender, family history, smoking, abnormal lipid
metabolism, and genetics [1]. T2DM is associated with
several comorbidities, including retinopathy, nephropa-
thy, and especially cardiovascular disease (CVD) [2].
CVD is a major complication of T2DM. An individ-
ual’s risk for CVD is two to four times greater if they
have T2DM relative to an individual not affected by
T2DM [3,4]. In 2007, heart disease was noted on the
death certificates of 68% of individuals with diabetes
[2,5]. Diabetes is an independent CVD risk factor, with
relative risk for CVD-associated mortality 2.1 for men
and 4.9 for women compared to those not affected by
T2DM [3,4]. There is increasing evidence that both gen-
etic and environmental factors contribute to this risk.
CVD risk can be assessed in many ways. A widely used
measure of subclinical CVD is coronary artery calcified
plaque (CAC) assessed by computed tomography (CT)
imaging. CAC is a powerful predictor of all-cause and
CVD-related mortality [5-7]. Calcified atherosclerotic
plaque (CP) can also be measured in the carotid artery
(CarCP) and infra-renal abdominal aorta (AACP). An-
other widely used measure is thickness of the intima
media layer of the carotid arteries (IMT) [7]. Import-
antly, CAC and IMT appear to capture different aspects
of CVD [6].
Identification of heritable risk factors for CVD and
other complications of T2DM are important to improve
our understanding of an individual’s risk. An extensive
genetic analysis of CVD in the general population was
recently performed in the Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) consor-
tium [8,9]. These studies consisted of genome wide asso-
ciation study (GWAS) meta-analyses identifying loci
associated with CAC, myocardial infarction (MI), and
IMT. These studies identified multiple CVD associated
loci. However, less than 10% of the CHARGE samples
were affected by T2DM. In the present study, the rele-
vance of the CHARGE results were tested in a T2DM-
enriched sample from the Diabetes Heart Study (DHS),
where more than 80% of subjects had T2DM [5,7].
Methods
Subjects
The DHS evaluates the genetic and epidemiological
causes of CVD in individuals with T2DM. Ascertain-
ment, recruitment, and examination have been described
in detail [7]. Briefly, siblings with T2DM and without ad-
vanced nephropathy were recruited, with unaffected sib-
lings also recruited when possible. T2DM was defined as
diabetes developing after 35 years of age, with initial
treatment using a combination of, exercise and/or oralagents, not solely insulin, and in the absence of historical
evidence of ketoacidosis. Diabetes diagnosis was con-
firmed upon entrance to the study by measurement of
fasting glucose and glycated hemoglobin (HbA1C) test-
ing. The 1,208 European American individuals included
in this analysis were from 473 families.
Clinical evaluation
Study protocols were approved by the Institutional Re-
view Board at Wake Forest School of Medicine. Partici-
pants provided written informed consent prior to
participation. Examinations were conducted in the
General Clinical Research Center of the Wake Forest
Baptist Medical Center and included interviews for
medical history and health behaviors, anthropometric
measures, resting blood pressure, electrocardiography,
fasting blood sampling for laboratory analyses (blood
lipid profile, fasting glucose, HbA1C, and high-sensitivity
C-reactive protein (CRP)) and spot urine collection. In-
dividuals were considered hypertensive if they were pre-
scribed anti-hypertensive medication or had blood
pressure measurements exceeding 140 mmHg (systolic)
or 90 mmHg (diastolic).
CAC, CarCP, and AACP were measured using fast-
gated helical CT scanning, and calcium scores were com-
puted as previously described and reported as Agatston
scores [10,11]. IMT was measured by high-resolution B-
mode ultrasonography with a 7.5-MHz transducer and a
Biosound Esaote (AU5) ultrasound machine (Biosound
Esaote, Inc., Indianapolis, IN) as previously described [12].
Not all measurements were available in all participants.
Vital status was determined from the National Social
Security Death Index maintained by the United States
Social Security Administration. For those participants
confirmed as deceased, length of follow-up was deter-
mined from date of the initial study visit to date of death
[6,13]. For deceased participants, copies of death certifi-
cates were obtained from relevant county Vital Records
Offices to confirm cause of death. For all other partici-
pants the length of follow-up was determined from the
date of the initial study visit to the December 31, 2012.
Causes of death were categorized based on information
contained in death certificates as CVD-related (myocardial
infarction, congestive heart failure, cardiac arrhythmia,
sudden cardiac death, peripheral vascular disease, and
stroke) or either cancer, infection, end-stage renal disease,
accidental, or other (including obstructive pulmonary dis-
ease, pulmonary fibrosis, liver failure and Alzheimer’s
dementia).
DHS GWAS and imputed data
Genomic DNA was purified from whole-blood samples
obtained from subjects using the PUREGENE DNA iso-
lation kit (Gentra Systems., Minneapolis, MN). DNA
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ings on a Hoefer DyNA Quant 200 fluorometer (Hoefer
Pharmacia Biotech, Inc., San Francisco, CA). Each sam-
ple was diluted to a final concentration of 5 ng/μL.
A GWAS was completed using the Affymetrix
Genome-wide Human SNP Array 5.0 (Affymetrix, CA,
USA) as reported [14]. Genotype calling was completed
using the BRLLM-P algorithm in Genotyping Console
v4.0 (Affymetrix). Samples failing to meet an intensity
quality control (QC) threshold and those failing to meet
a minimum acceptable call rate of 95% were excluded
from further analyses (n = 7). An additional 39 samples
were included as blind duplicates within the genotyping
set to serve as QC samples; the concordance rate for
these blind duplicates was 99.0 ± 0.72% (mean ± stand-
ard deviation (SD)). Exploratory analyses of genotype
data were performed using PLINK v1.07 (http://pngu.
mgh.harvard.edu/purcell/plink/) and samples with poor
quality genotype calls, gender errors, or unclear/unex-
pected sibling relationships were excluded from further
analysis. Exclusion criteria for single nucleotide poly-
morphism (SNP) performance included call rate <95%
(n = 11,085), Hardy-Weinberg Equilibrium (HWE) p-
value <1×10−6 (n = 332), and minor allele frequency
(MAF) <0.01 (n = 57,382); 371,951 SNPs were retained
for analysis.
Additional genotype data were obtained by imputation
from the GWAS. Imputation of 1,000 Genomes Project
SNPs was completed using the program IMPUTE2 (http://
mathgen.stats.ox.ac.uk/impute/impute_v2.html) and the
Phase I v2, cosmopolitan (integrated) reference panel,
build 37 [15]. SNPs that were used for imputation were re-
quired to have low missingness and show no significant
departure from HWE expectations. To maximize the
quality of imputation, the samples were not pre-phased.
Only imputed SNPs with a confidence score >0.90 and in-
formation score >0.50 were used.
Individual SNP genotyping
For those genes implicated in the CHARGE meta-
analyses as potential risk loci, exonic variants contained
in the National Heart Lung and Blood Institute Grand
Opportunity Exome Sequencing Project (NHLBI GO-
ESP). Coding SNPs identified as possibly damaging or
probably damaging by PolyPhen2 [16] with a minor al-
lele frequency (MAF) less than 0.2 were selected for
genotyping. Fourty-four single nucleotide polymor-
phisms (SNPs) from 17 genes were genotyped in the
DHS. Genotyping was performed using the Sequenom
Mass ARRAY genotyping system (Sequenom, San Diego,
CA) and PCR primers were designed using the Mass
ARRAY Assay Design 3.4 Software (Sequenom). An add-
itional 41 quality control (QC) samples were included in
the genotyping analysis to serve as blind duplicates. Theconcordance rate for the blind duplicates was 100%. For
all SNPs the minimum acceptable call frequency was
95%. The average call frequency was 97.3 ± 0.009%
(mean ± SD). Samples with genotyping efficiency rates
<90% were excluded from further analysis. Twenty-eight
SNPs from 14 genes were carried forward to analysis
after QC. Genotyped SNPs are listed in Additional file 1.
Exome chip
Additional SNPs for those genes implicated in the
CHARGE meta-analyses as potential risk loci were also
identified as captured by the Illumina® HumanExome
BeadChips (Illumina® Inc., San Diego, CA) for which
genotype data was available in the DHS. For DHS Ex-
ome Chip data, genotype calling was completed using
Genome Studio Software v1.9.4 (Illumina). Samples failing
to meet a minimum acceptable call rate of 98% (n = 3)
were excluded from further analyses. An additional 58
samples were included as blind duplicates within the
genotyping set to serve as QC samples; the concordance
rate for blind duplicates was 99.9 ± 0.0001% (mean ± SD).
Exclusion criteria for SNP performance included call rate
<99% (n = 972), monomorphic SNPs (n = 157,754) and
Hardy-Weinberg Equilibrium p-value <1×10−6 (n = 26);
88,483 SNPs were retained for analysis. Additional QC of
Exome Chip data set was completed to exclude samples
with poor quality genotype calls, gender errors, or un-
clear/unexpected sibling relationships.
Genetic risk scores
Genetic risk scores (GRS) were calculated as previously
described [17]. Both unweighted GRS and GRS weighted
by SNP effect size were derived for two sets of SNPs
previously reported to be associated with CAC or CAC
and MI. SNPs included in both GRS are shown in
Additional file 2. One set of 12 SNPs had documented
effects on CAC (Score 1; 1a = unweighted, 1b = weighted).
We created a second GRS from 8 SNPs associated with
CAC and MI (Score 2; 2a = unweighted, 2b = weighted).
Unweighted scores were derived by adding the number
of effect alleles for each SNP for each person. The SNPs
were also weighted by their previously reported effect
sizes [8,9]. For the weighted scores, the number of effect
alleles possessed by an individual at a particular SNP
locus was multiplied by a weight derived from that SNP’s
effect size contribution to the total effect size for all
SNPs included in the GRS. For individuals missing
genotype data for a particular SNP, the mean genotype
calculated in the DHS for that given SNP was assigned
[18]. For all GRS, the effect allele was assigned as the
allele associated with an increase in CAC or increased
risk for CAC.
All derived GRS (1a, 1b, 2a, and 2b) were tested for as-
sociation with CAC, CarCP, AACP, IMT, prior history of
Table 1 Demographic characteristics of DHS samples
(data shown are mean ± SD, unless specified otherwise)
Total
Number 1208
Age 61.5 ± 9.35
Female (%) 643 (53.2)
BMI (kg/m2) 31.8 ± 6.49
T2DM Affected (%) 1013 (83.9)
Diabetes duration (years) 10.41 ± 7.1
Metabolic syndrome (%) 1029 (85.2)
Lipid medication (%) 540 (44.7)
CAC 1662.5 ± 3160.7
CarCP 312.9 ± 672.1
AACP 10949.3 ± 15748.8
IMT (mm) 0.676 ± 0.134
Cholesterol (mg/dL) 186.8 ± 42.4
LDL (mg/dL) 105.1 ± 32.7
HDL (mg/dL) 43.1 ± 12.5
Triglycerides (mg/dL) 201.4 ± 132.1
History of CVD (%) 471 (38.99)
Deceased (%) 222 (18.38)
CVD Deceased (% of deceased) 100 (45.05)
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CVD-cause mortality to evaluate whether the GRS were
a measure of genetic contributions to either clinical or
subclinical CVD.
Statistical analysis
Allele frequencies were calculated for a sub-set of unre-
lated individuals and departure from HWE was calculated
from a group of unrelated samples using a chi-squared
goodness-of-fit test implemented in PLINK v1.07. Associ-
ation between the SNP genotypes and CVD measures was
examined using variance component methods computed
using SOLAR v4.3.1 (Texas Biomedical Research Institute,
San Antonio, Tx, USA) which accounted for family struc-
ture. Each trait was examined using additive, dominant,
and recessive models of inheritance. Most of the associa-
tions were observed under the additive model, however,
there were associations seen under only the dominant or
recessive models. Continuous variables were transformed
prior to analysis to approximate conditional normality.
Age, gender, T2DM-affection status, and body mass index
(BMI) were used as covariates in all single variant associ-
ation analyses. Additional covariates (e.g. cholesterol
medication use, T2DM duration, and smoking) were also
tested, but did not meaningfully impact the results. Statis-
tical significance for all single SNP analysis was calculated
using the Li & Ji method to determine the effective num-
ber of SNPs using SOLAR v. 4.3.1. Statistical significance
was set at p < 2.16×10−4. Power calculations for dichotom-
ous traits were run using CaTS (University of Michigan
School of Public Health http://www.sph.umich.edu/csg/
abecasis/CaTS/). Power calculations for continuous traits
were run using Quanto (University of Southern California
http://hydra.usc.edu/gxe/).
GRS were considered as continuous variables. Rela-
tionships between the GRS and CAC, CarCP, AACP, his-
tory of CVD, and history of MI were examined using
marginal models with incorporation of generalized esti-
mating equations. These models use a sandwich estima-
tor of the variance under exchangeable correlation in
order to account for familial correlation [17]. Relation-
ships between GRS and both all-cause and CVD-cause
mortality were examined using Cox proportional hazards
models with sandwich-based variance estimation due to
the inclusion of related individuals. Associations were
adjusted for age, gender, BMI, smoking status (current
or prior smoking), hypertension, cholesterol medica-
tions, and prior CVD as indicated. All analyses were per-
formed in SAS 9.3 (SAS Institute, Cary, NC) and
statistical significance was accepted at p < 0.05.
Results
Characteristics of the DHS sample are summarized in
Table 1. The mean age of the sample was 61.5 years atexamination. 1013 (83.86%) were T2DM-affected, the
mean BMI approached 32 kg/m2, and slightly more than
50% (643) were female. The characteristics of the DHS
samples are broadly representative of T2DM-affected pa-
tients in the general population: older, relatively obese,
and with significant risk factors and history of CVD.
We pursued multiple paths of analysis to assess the
relevance of genetic loci implicated in various measures
of CVD in the general population to another sample
enriched for T2DM. Thus specific SNPs from the
CHARGE subclinical CVD analysis [8,9] were tested in
silico or directly genotyped to test for association in the
DHS. In addition, the analysis has been expanded to in-
clude additional coding variants from the CHARGE loci
risk and further expanded to assess the association of
GRS, i.e. the cumulative effect of multiple associated
SNPs, on CVD related traits. All analyses were per-
formed in a subset of T2D-affected individuals alone
and revealed similar results (data not shown).
Testing CHARGE variants from DHS GWAS and imputation
data
In an attempt to replicate the findings from the
CHARGE studies, a total of 36 SNPs with available
GWAS data were tested for association with clinical and
subclinical CVD traits as well as CVD risk factors. No
SNPs were significantly associated after correction for
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showed nominal association (Table 2). Among these,
rs599839 near PSRC1 (β = −0.31, p = 0.008) and rs646776
near CELSR2 (β = −0.38, p = 0.01) were nominally associ-
ated with CAC, while rs17398575 near PIK3CG was asso-
ciated with AACP (β = 11.0, p = 0.0054); and SNPs in
COL4A2 (rs3809346, rs4773144) and near CXCL12
(rs1746048) were nominally associated with all-cause or
CVD-cause mortality.
Genotyped SNP results
To investigate the genes implicated by the CHARGE
studies 28 exonic SNPs in 14 genes were identified in
the NHLBI GO-ESP database, directly genotyped in the
DHS and tested for association with clinical CVD, sub-
clinical CVD, and CVD risk factors. The mean MAF for
the genotyped SNPs were 0.0306 (0.0004-0.1617). The
genotyped SNPs, along with gene, amino acid change,
minor allele, and MAF can be found in Additional file 1.
Table 3 contains results from the association analysis
with the genotyped SNPs. Three SNPs were significantly
associated with CVD risk factors. rs3135506 (Ser19Trp)
in APOA5 was associated with increased triglyceride
(TG) (p = 5×10−5), nominally associated with decreased
low density lipoprotein (LDL)-cholesterol (p = 0.0007),
and nominally associated with decreased high density
lipoprotein (HDL)-cholesterol (p = 0.0066). rs651821 (5′
untranslated region (UTR)) also in APOA5, was nomin-
ally associated with increased TG concentration (p =
0.00080) while rs138326449 (splice donor) in APOC3
was associated with decreased TG concentrations (p =
0.0015). Several other SNPs including rs45456595
(CDKN2A, Gly63Arg), rs5128 (APOC3, 3′UTR), and
rs72650673 (SH2B3, Glu400Lys) were nominally associ-
ated (at p < 0.010) with history of CVD, subclinical CVD,
or CVD risk factors.
Exome chip results
At total of 209 exonic SNPs with available genotype data
from the exome chip were evaluated for association with
clinical CVD, subclinical CVD, and CVD risk factors.Table 2 Nominally significant results for the GWAS and impu
Addi
SNP Gene Trait P-value β v
rs1746048 CXCL12 All-cause mortality 0.005 0
rs599839 PSRC1 CAC 0.008 −
rs646776 CELSR2, PSRC1, SORT1 CAC 0.013 −
rs17398575 PIK3CG AACP 0.015 8
rs3809346 COL4A1, COL4A2 CVD-cause mortality 0.026 −
rs4773144 COL4A1, COL4A2 CVD-cause mortality 0.040 −
Associations were examined under additive, dominant and recessive genetic mode
calcified plaque SE = standard error.Table 4 shows the significant results for the association
of the SNPs from the Exome chip with subclinical and
clinical CVD traits as well as CVD risk factors. One SNP
rs3750103 (His204Arg/His68Arg) in CHN2 was associ-
ated with IMT under the recessive model (β = 0.17, p =
3.9×10−5). A second SNP, rs61937878 (Val549Met) in
HAL was significantly associated with AACP (β = 85.5,
p = 7.1×10−5). Additional SNPs (rs61735307, SERPINI1;
rs10496236, CTNNA2; rs11073922, NGRN) were nom-
inally associated with various lipid measures IMT.
Genetic risk score
Finally, we determined the combined effect of the CHARGE
SNPs on CVD traits. We analyzed 4 genetic risk scores
containing different sets of SNPs and weighting method
combinations for potential associations with CAC, CarCP,
AACP, prior history of CVD, prior history of MI, and all-
cause and CVD-cause mortality. The unweighted GRS
containing CAC associated SNPs (GRS 1a) was associated
with history of CVD events (p = 0.033; OR = 1.09). GRS
2b, the weighted risk score containing SNPs associated
with both CAC and MI, was associated with history of MI
(p = 0.026; OR = 1.15). No other associations were ob-
served. Significant results for the GRS analysis are shown
in Table 5.
Discussion
We assessed whether results seen in the CHARGE con-
sortium GWAS meta-analyses were applicable to a
T2DM enriched sample in the DHS. In addition,
CHARGE analyses were extended by including coding
variants in genes implicated in the CHARGE studies and
testing GRS created from combinations of SNPs previ-
ously associated in CHARGE. We were unable to detect
any associations that reached statistical significance in
the initial analysis of CHARGE top-hit SNPs when ap-
plying a conservative Bonferoni correction; however sev-
eral nominal associations were observed with clinical
and subclinical CVD traits (Table 2).
A further investigation into the genes implicated in
this study reveal a wide range of biological functions.tation SNPs with measures of CVD and lipids
tive Dominant Recessive
alue SE P-value β value SE P-value β value SE
.29 0.12 0.005 0.32 0.12 0.28 0.43 0.44
0.31 0.12 0.009 −0.36 0.14 0.27 −0.36 0.32
0.31 0.12 0.010 −0.38 0.15 0.41 −0.28 0.34
.74 3.58 0.009 11.03 4.20 0.60 4.85 9.33
0.18 0.08 0.36 −0.11 0.12 0.004 −0.39 0.14
0.16 0.08 0.43 −0.095 0.12 0.007 −0.38 0.14
ls. CAC = coronary artery calcified plaque; AACP = infrarenal abdominal aortic
Table 3 Association results for the genotyped exonic variants with clinical and subclinical CVD and blood lipids
Additive Dominant Recessive
SNP Trait P-value β value SE P-value β value SE P-value β value SE
rs3135506 Triglycerides 5×10−5 0.189 0.465 3×10−4 0.17 0.31 7×10−4 0.93 0.27
rs3135506 LDL 0.0012 −9.48 2.92 7×10−4 −10.1 2.99 0.65 10.1 22.4
rs3135506 HDL 0.0066 −0.20 0.07 0.011 −0.19 0.07 0.13 −0.63 0.42
rs651821 Triglycerides 8×10−4 0.15 0.04 0.004 0.14 0.05 0.005 0.5 0.18
rs651821 History of CVD 0.02 0.27 0.11 0.08 0.23 0.13 0.009 1.29 0.56
rs138326449 Triglycerides 0.0017 −0.97 0.31 0.0017 −0.97 0.31 NA NA NA
rs138326449 HDL 0.13 1.16 0.46 0.013 1.16 0.46 NA NA NA
rs45456595 IMT 0.0022 0.07 0.02 0.0022 0.07 0.02 NA NA NA
rs5128 Triglycerides 0.0096 0.10 0.04 0.03 0.09 0.04 0.01 0.41 0.16
rs72650673 Triglycerides 0.0084 0.77 0.29 0.0084 0.77 0.29 NA NA NA
Associations were examined under additive, dominant and recessive genetic models. Bold indicates statistical significance. History of CVD = prior reports of CVD
events, IMT = carotid intima-media thickness, SE = standard error.
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biological rationales. SNPs rs3809346 and rs4773144 lo-
cated in the COL4A2 gene were nominally associated
with CVD mortality (Table 2). COL4A2 encodes the pro-
tein collagen type IV alpha 2 which is the major compo-
nent of basement membranes [19]. SNP rs17398575,
near PIK3CG, was nominally associated with AACP.
PIK3CG encodes for an enzyme that phosphorylates
phosphoinositides. It is an important modulator of extra-
cellular signals, including those elicited by E-cadherin-
mediated cell-cell adhesion, with an important role in
maintenance of the structural and functional integrity of
epithelia [20]. Rs1746048, nominally associated with all-
cause mortality (p-value of 0.005), is downstream of
CXCL12. CXCL12 encodes a stromal cell-derived alpha
chemokine which can activate lymphocytes and may have
a role in the cancer metastasis [21]. It is also a chemo-
attractant for T-lymphocytes and monocytes [22]. Activ-
ities of this protein and its receptor induce a rapid rise in
the level of intracellular calcium ions and chemotaxis.
Rs646776, downstream of CELSR2, was nominally associ-
ated with CAC. CELSR2 encodes for a protein in the
cadherin family that does not interact with catenins. It is
thought that these proteins are involved in contact-Table 4 Association results for SNPs from the DHS Exome Chi
Additive
SNP Trait P-value β value SE P
rs3750103 IMT 0.35 0.007 0.007
rs61937878 AACP 7.1×10−5 85.45 21.38 7.
rs61735307 IMT 2.6×10−4 0.24 0.06 2
rs10496236 Cholesterol 3.2×10−4 −0.05 0.02
rs11073922 IMT 0.21 0.007 0.005
Associations were examined under additive, dominant and recessive genetic mode
calcified plaque, IMT = carotid intima-media thickness, SE = standard error.mediated communication. However, the specific function
has not been determined. CELSR2 and PSRC1 (rs599839)
have been associated with both coronary artery disease
and total cholesterol concentration [23].
We further investigated the genes implicated by the
CHARGE studies by genotyping exonic SNPs and investi-
gated further exonic SNPs from the DHS Exome chip. Ex-
onic SNPs from CAC- and CVD-associated genes in
CHARGE were found to be associated with lipid traits in
DHS (Table 3). Additional coding variants were asociated
with subclinical CVD traits and CVD risk factors (Table 4).
Several genes with known relevant biological functions
were found in the investigation of coding SNPs. APOA5
(rs3135506, associated with TG concentrations and
nominally with LDL concentrations; p-value = 5×10−5
and 7×10−4 respectively, and rs651821, nominally associ-
ated with triglyceride concentrations; p-value = 8×10−4;
Table 3), which is a component of HDL, was shown as-
sociated with TG concentrations and coronary artery
disease [24,25]. APOC3, a component of very low dens-
ity lipoprotein (VLDL), is thought to delay catabolism of
TG-rich particles and impact TG concentrations [26]. In
DHS, APOC3 was nominally associated with TG concen-
trations and HDL (rs138326449; p-value = 0.0017 andp with measures of CVD and cholesterol
Dominant Recessive
-value β value SE P-value β value SE
0.81 0.002 0.007 3.9×10−5 0.17 0.04
1×10−5 85.45 21.38 NA NA NA
.6×10−4 0.24 0.06 NA NA NA
0.0032 0.0031 0.02 9.2×10−4 −0.16 0.05
0.71 0.002 0.006 7.2×10−4 0.06 0.019
ls. Bold indicates statistical significance. AACP = infrarenal abdominal aortic
Table 5 Significant association results for the GRS with
CVD
GRS Trait P-value OR 95% CI
1a History of CVD 0.033 1.09 1.01 – 1.19
2b History of MI 0.026 1.15 1.02 – 1.34
Bold indicates statistical significance. History of CVD = prior reports of CVD
events, History of MI = prior reports of Myocardial Infarction, GRS = genetic
risk score, 1a = unweighted risk score with CAC associated SNPs, 2b = weighted
risk score with CAC and MI associated SNPs, OR = odds ratio, 95% CI = 95%
confidence interval.
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(Table 3). SNP rs3750103 in CHN2 was associated with
IMT with a p-value 3.9×10−5 (Table 4). CHN2 encodes
for the protein chimerin 2, which plays a role in the pro-
liferation and migration of smooth muscle cells [27]. A
second SNP, rs61937878, associated with AACP (p-value =
7.1×10−5; Table 4), is located in HAL. HAL encodes
the protein histidine ammonia-lyase, which catalyzes
the first step in histidine catabolism. Finally rs10496236 in
CTNNA2 was nominally associated with total cholesterol
concentrations (p-value = 3.2×10−4; Table 4). CTNNA2 en-
codes for catenin (cadherin-associated protein), alpha 2
which functions as a linker between cadherin adhesion re-
ceptors and the cytoskeleton to regulate cell-cell adhesion,
predominantly in the central nervous system, and it has
been associated with late onset Alzheimer’s disease [28].
Finally, we assessed whether GRS of CHARGE SNPs
associated with CAC or CAC and MI provides a useful
tool to predict CAC or CVD in the DHS. We found that
GRS containing CAC risk SNPs or SNPs associated with
increased CAC and MI were associated with CVD
events in the DHS (Table 5). This indicates that CAC
risk SNPs have potential to be used for identification of
CVD risk in populations enriched for T2DM. The
present studies were performed in European American
subjects; results require replication in members of other
population ancestries.
An important consideration in any study of this type is
the statistical power of the study. This study has moder-
ate power to identify associations with dichotomous trait
and very high power to detect associations with continu-
ous traits. For example, at a MAF of 0.35 we have 40%
power to detect an association with history of CVD with
an odds ratio of 1.15. For a quantitative trait example,
this study has greater than 80% power to detect an asso-
ciation between a SNP with 0.11 MAF and a β-value of
0.1 for triglyceride levels.
Conclusions
Taken together, these results provide evidence that the
variants and genes implicated by the earlier CHARGE
association studies affect clinical and subclinical CVD
risk as well as CVD risk factors in European American
individuals with T2DM. This study investigated knownor suspected CVD associated variants and genes. How-
ever, these variants may not account for the individual’s
full risk as there may be additional risk variants that are
not covered by conventional techniques such as the
Haptoglobin duplication [29]. Additional studies need to
be performed to investigate the regions of the genome that
aren’t easily covered by modern genotyping technology.
Additional files
Additional file 1: Genotyped SNPs carried forward to analysis for
clinical and subclinical CVD as well as blood lipid traits. MA %, Minor
Allele %.
Additional file 2: List of SNPs used in the GRS. GRS 1a and 1b
contained SNPs associated with CAC. GRS 2a and 2b contained SNPs
associated with CAC and MI.
Abbreviations
AACP: Infra-renal abdominal aortic calcified plaque; BMI: Body mass index;
CAC: Coronary artery calcified plaque; CarCP: Carotid artery calcified plaque;
CHARGE: Cohorts for Heart and Aging Research in Genomic Epidemiology;
CRP: C-reactive protein; CVD: Cardiovascular disease; DHS: Diabetes Heart
Study; GRS: Genetic risk score; GWAS: Genome wide association study;
HbA1c: Glycated hemoglobin; HDL: High density lipoprotein; IMT: Intima
media thickness; LDL: Low density lipoprotein; MAF: Minor allele frequency;
MI: Myocardial infarction; NHLBI GO-ESP: National Heart Lung and Blood
Institute Grand Opportunity Exome Sequencing Project; QC: Quality control;
SNP: Single nucleotide polymorphism; SD: Standard deviation;
TG: Triglycerides; T2DM: Type 2 diabetes mellitus; UTR: Untranslated region;
VLDL: Very low density lipoprotein.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
JNA perfomed the SNP genotyping, calculated the GRS, performed all the
statistical analysis, and wrote the manuscript; LMR assisted in the calculation
of the GRS and reviewed the manuscript; BIF was involved in the conception
of the DHS, participated in subject recruitment and clinical assessment, and
reviewed the manuscript; CDL performed the GWAS imputation, contributed
to statistical analyses, and reviewed the manuscript; MCYN assisted with the
calculation of the GRS and reviewed the manuscript; JJC was involved in the
conception of the DHS, participated in subject recruitment and clinical
assessment, and reviewed the manuscript; AJC performed the clustering and
QC for the DHS GWAS and Exome Chip, performed the GWAS and Exome
association analyses, and assisted with the manuscript preparation; DWB
designed and supervised the DHS, conceived the investigation, and assisted
with the manuscript preparation. All authors read and approved the final
manuscript.
Acknowledgements
This study was supported in part by R01 HL67348, R01 HL092301, and R01
NS058700 (to DWB). The authors thank the other investigators, the staff, and
the participants of the Diabetes Heart Study for their valuable contributions.
Author details
1Program in Molecular Genetics and Genomics, Wake Forest School of
Medicine, Winston-Salem, NC 27157, USA. 2Center for Genomics and
Personalized Medicine Research, Wake Forest School of Medicine,
Winston-Salem, NC 27157, USA. 3Center for Diabetes Research, Wake Forest
School of Medicine, Winston-Salem, NC 27157, USA. 4Department of Internal
Medicine – Nephrology, Wake Forest School of Medicine, Winston-Salem, NC
27157, USA. 5Division of Public Health Sciences, Department of Biostatistical
Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.
6Department of Radiologic Sciences, Wake Forest School of Medicine,
Winston-Salem, NC 27157, USA. 7Department of Biochemistry, Wake Forest
School of Medicine, Winston-Salem, NC 27157, USA.
Adams et al. Cardiovascular Diabetology 2014, 13:77 Page 8 of 8
http://www.cardiab.com/content/13/1/77Received: 14 January 2014 Accepted: 26 March 2014
Published: 12 April 2014
References
1. O’Donnell CJ, Elosua R: Cardiovascular risk factors. Insights from
Framingham Heart Study. Rev Esp Cardiol 2008, 61(3):299–310.
2. Centers for Disease Control and Prevention: National Diabetes Fact Sheet:
National Estimates And General Information On Diabetes And
Prediabetes In The United States, 2011. In Atlanta, GA: U.S: Department of
Health and Human Services, Centers for Disease Control and Prevention;
2011.
3. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint
editorial statement by the American Diabetes Association; The National
Heart, Lung, and Blood Institute; The Juvenile Diabetes Foundation
International; The National Institute of Diabetes and Digestive and
Kidney Diseases; and The American Heart Association. Circulation 1999,
100(10):1132–1133.
4. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The
Framingham study. JAMA 1979, 241(19):2035–2038.
5. Bowden DW, Cox AJ, Freedman BI, Hugenschimdt CE, Wagenknecht LE,
Herrington D, Agarwal S, Register TC, Maldjian JA, Ng MC, Hsu FC,
Langefeld CD, Williamson JD, Carr JJ: Review of the Diabetes Heart Study
(DHS) family of studies: a comprehensively examined sample for genetic
and epidemiological studies of type 2 diabetes and its complications.
Rev Diabet Stud 2010, 7:188–201.
6. Agarwal S, Cox AJ, Herrington DM, Jorgensen NW, Xu J, Freedman BI, Carr
JJ, Bowden DW: Coronary calcium score predicts cardiovascular mortality
in diabetes: diabetes heart study. Diabetes Care 2013, 36(4):972–977.
7. Bowden DW, Lehtinen AB, Ziegler JT, Rudock ME, Xu J, Wagenknecht LE,
Herrington DM, Rich SS, Freedman BI, Carr JJ, Langefeld CD: Genetic
epidemiology of subclinical cardiovascular disease in the diabetes heart
study. Ann Hum Genet 2008, 72:598–610.
8. Bis JC, Kavousi M, Franceschini N, Isaacs A, Abecasis GR, Schminke U, Post
WS, Smith AV, Cupples LA, Markus HS, Schmidt R, Huffman JE, Lehtimaki T,
Baumert J, Munzel T, Heckbert SR, Dehghan A, North K, Oostra B, Bevan S,
Stoegerer EM, Hayward C, Raitakari O, Meisinger C, Schillert A, Sanna S,
Volzke H, Cheng YC, Thorsson B, Fox CS, et al: Meta-analysis of genome-
wide association studies from the CHARGE consortium identifies
common variants associated with carotid intima media thickness and
plaque. Nat Genet 2011, 43:940–947.
9. O'Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwang SJ, Sun YV,
Province MA, Aspelund T, Dehghan A, Hoffmann U, Bielak LF, Zhang Q,
Eiriksdottir G, van Duijn CM, Fox CS, de Andrade M, Kraja AT, Sigurdsson S,
Elias-Smale SE, Murabito JM, Launer LJ, van der Lugt A, Kathiresan S, Krestin
GP, Herrington DM, Howard TD, Liu Y, Post W, Mitchell BD, et al: Genome-
wide association study for coronary artery calcification with follow-up in
myocardial infarction. Circulation 2011, 124:2855–2864.
10. Carr JJ, Nelson JC, Wong ND, McNitt-Gray M, Arad Y, Jacobs DR Jr, Sidney S,
Bild DE, Williams OD, Detrano RC: Calcified coronary artery plaque
measurement with cardiac CT in population-based studies: standardized
protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary
Artery Risk Development in Young Adults (CARDIA) study. Radiology
2005, 234(1):35–43.
11. Carr JJ, Crouse JR 3rd, Goff DC Jr, D’Agostino RB Jr, Peterson NP, Burke GL:
Evaluation of subsecond gated helical CT for quantification of coronary
artery calcium and comparison with electron beam CT. AJR Am J
Roentgenol 2000, 174(4):915–921.
12. Lange LA, Bowden DW, Langefeld CD, Wagenknecht LE, Carr JJ, Rich SS,
Riley WA, Freedman BI: Heritability of carotid artery intima-medial
thickness in type 2 diabetes. Stroke 2002, 33(7):1876–1881.
13. Agarwal S, Morgan T, Herrington DM, Xu J, Cox AJ, Freedman BI, Carr JJ,
Bowden DW: Coronary calcium score and prediction of all-cause
mortality in diabetes: the diabetes heart study. Diabetes Care 2011,
34(5):1219–1224.
14. Cox AJ, Ng MC, Xu J, Langefeld CD, Koch KL, Dawson PA, Carr JJ, Freedman
BI, Hsu FC, Bowden DW: Association of SNPs in the UGT1A gene cluster
with total bilirubin and mortality in the Diabetes Heart Study.
Atherosclerosis 2013, 229(1):155–160.
15. Howie BN, Donnelly P, Marchini J: A flexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet 2009, 5(6):e1000529.16. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P,
Kondrashov AS, Sunyaev SR: A method and server for predicting
damaging missense mutations. Nat Methods 2010, 7(4):248–249.
17. Raffield LM, Cox AJ, Hsu FC, Ng MC, Langefeld CD, Carr JJ, Freedman BI,
Bowden DW: Impact of HDL genetic risk scores on coronary artery
calcified plaque and mortality in individuals with type 2 diabetes from
the Diabetes Heart Study. Cardiovasc Diabetol 2013, 12:95.
18. Fontaine-Bisson B, Renström F, Rolandsson O, Magic, Payne F, Hallmans G,
Barroso I, Franks P: Evaluating the discriminative power of multi-trait
genetic risk scores for type 2 diabetes in a northern Swedish population.
Diabetologia 2010, 53(10):2155–2162.
19. Griffin CA, Emanuel BS, Hansen JR, Cavenee WK, Myers JC: Human collagen
genes encoding basement membrane alpha 1 (IV) and alpha 2 (IV)
chains map to the distal long arm of chromosome 13. Proc Natl Acad Sci
U S A 1987, 84(2):512–516.
20. Tibolla G, Pineiro R, Chiozzotto D, Mavrommati I, Wheeler AP, Norata GD,
Catapano AL, Maffucci T, Falasca M: Class II phosphoinositide 3-kinases
contribute to endothelial cells morphogenesis. PLoS One 2013,
8(1):e53808.
21. Singh S, Singh UP, Grizzle WE, Lillard JW Jr: CXCL12-CXCR4 interactions
modulate prostate cancer cell migration, metalloproteinase expression
and invasion. Lab Invest 2004, 84(12):1666–1676.
22. Man S, Tucky B, Cotleur A, Drazba J, Takeshita Y, Ransohoff RM: CXCL12-
induced monocyte-endothelial interactions promote lymphocyte
transmigration across an in vitro blood–brain barrier. Sci Transl Med 2012,
4(119):119ra114.
23. Samani NJ, Braund PS, Erdmann J, Gotz A, Tomaszewski M, Linsel-Nitschke
P, Hajat C, Mangino M, Hengstenberg C, Stark K, Ziegler A, Caulfield M,
Burton PR, Schunkert H, Tobin MD: The novel genetic variant predisposing
to coronary artery disease in the region of the PSRC1 and CELSR2 genes
on chromosome 1 associates with serum cholesterol. J Mol Med (Berl)
2008, 86:1233–1241.
24. Pennacchio LA, Olivier M, Hubacek JA, Krauss RM, Rubin EM, Cohen JC: Two
independent apolipoprotein A5 haplotypes influence human plasma
triglyceride levels. Hum Mol Genet 2002, 11(24):3031–3038.
25. Lai CQ, Demissie S, Cupples LA, Zhu Y, Adiconis X, Parnell LD, Corella D,
Ordovas JM: Influence of the APOA5 locus on plasma triglyceride,
lipoprotein subclasses, and CVD risk in the Framingham Heart Study.
J Lipid Res 2004, 45(11):2096–2105.
26. Russo GT, Meigs JB, Cupples LA, Demissie S, Otvos JD, Wilson PW, Lahoz C,
Cucinotta D, Couture P, Mallory T, Schaefer EJ, Ordovas JM: Association of
the Sst-I polymorphism at the APOC3 gene locus with variations in lipid
levels, lipoprotein subclass profiles and coronary heart disease risk: the
Framingham offspring study. Atherosclerosis 2001, 158:173–181.
27. Maeda M, Kato S, Fukushima S, Kaneyuki U, Fujii T, Kazanietz MG, Oshima K,
Shigemori M: Regulation of vascular smooth muscle proliferation and
migration by beta2-chimaerin, a non-protein kinase C phorbol ester
receptor. Int J Mol Med 2006, 17(4):559–566.
28. Cummings AC, Jiang L, Velez Edwards DR, McCauley JL, Laux R, McFarland
LL, Fuzzell D, Knebusch C, Caywood L, Reinhart-Mercer L, Nations L, Gilbert
JR, Konidari I, Tramontana M, Cuccaro ML, Scott WK, Pericak-Vance MA,
Haines JL: Genome-wide association and linkage study in the Amish
detects a novel candidate late-onset Alzheimer disease gene. Ann Hum
Genet 2012, 76:342–351.
29. Adams JN, Cox AJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW:
Genetic analysis of haptoglobin polymorphisms with cardiovascular
disease and type 2 diabetes in the Diabetes Heart Study. Cardiovasc
Diabetol 2013, 12:31.
doi:10.1186/1475-2840-13-77
Cite this article as: Adams et al.: Analysis of common and coding
variants with cardiovascular disease in the diabetes heart study.
Cardiovascular Diabetology 2014 13:77.
